<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Park, Jeong Bae</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Metabolic Syndrome Elevates Risk of Microalbuminuria despite BP Control</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">Fimasartan reduced blood pressure (BP) and albumin-creatinine ratio (ACR) in patients with or without metabolic syndrome; however, patients with metabolic syndrome at baseline and 3 months were at a greater risk of elevated ACR at 1 year. This article presents 3-month and 1-year data from a 3-year multicenter study designed to evaluate the effect of early correction of metabolic syndrome on organ damage for patients with hypertension [K-METS]. The design of this study has been published [Kim C et al. Pulse 2013].</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>